v3.25.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
OPERATING EXPENSES            
General and administrative expenses         $ 3,088,671 $ 1,340,168
Total operating expenses         (3,088,671) (1,340,168)
Other income (expense):            
Change in fair value of subscription loan         (9,105,853)
Interest expense – debt discount         (891,624) (8,966)
Interest earned on investments held in Trust Account         548,676 5,813,213
Total other (expense) income, net         (9,448,801) 5,804,247
Net income (loss)         (12,537,472) 4,464,079
Aspire Biopharma Inc [Member]            
REVENUE            
Gross Receipts        
Net Revenue        
COST OF REVENUE            
Cost of goods sold        
Total cost of revenue        
GROSS PROFIT        
OPERATING EXPENSES            
General and administrative expenses         940,421 246,895
Research and development         144,356 72,050
Sales and Marketing         126,094 39,644
Total operating expenses         1,210,871 358,589
Other income (expense):            
Interest expense – debt discount         (97,988)
Total other (expense) income, net         (97,988)
Net gain/(loss) before income tax provision         (1,308,859) (358,589)
Provision for Income Taxes         1,013 481
Net income (loss)         $ (1,309,872) $ (359,070)
Weighted average shares outstanding, basic         507,353,659 481,794,521
Weighted average shares outstanding, diluted         507,353,659 481,794,521
Basic net (loss) income per share         $ (0.003) $ (0.001)
Diluted net (loss) income per share         $ (0.003) $ (0.001)
Parent Company [Member]            
OPERATING EXPENSES            
General and administrative expenses $ 395,692 $ 86,423 $ 15,469,240 $ 219,227    
Research and development 352,887 10,500 615,980 21,000    
Sales and Marketing 51,311 271,150 87,666    
Total operating expenses (799,890) (96,923) (16,356,370) (327,893)    
Other income (expense):            
Interest expense (527,893) (817,824)    
Interest expense – debt discount     (817,824)    
Change in fair value of derivative liability (289,401) (384,318)    
Loss on extinguishment of debt (364,109)   (364,109)    
Total other (expense) income, net (1,181,403) (1,566,251)    
Net income (loss) $ (1,981,293) $ (96,923) $ (17,922,621) $ (327,893)    
Common Class A [Member]            
Other income (expense):            
Weighted average shares outstanding, basic         8,244,188 16,461,668
Weighted average shares outstanding, diluted         8,244,188 16,461,668
Basic net (loss) income per share         $ (1.52) $ 0.23
Diluted net (loss) income per share         $ (1.52) $ 0.23
Common Class A [Member] | Parent Company [Member]            
Other income (expense):            
Weighted average shares outstanding, basic 49,333,662 27,601,374 43,693,010 27,593,513    
Weighted average shares outstanding, diluted 49,333,662 27,601,374 43,693,010 27,593,513    
Basic net (loss) income per share $ (0.04) $ (0.00) $ (0.41) $ (0.01)    
Diluted net (loss) income per share $ (0.04) $ (0.00) $ (0.41) $ (0.01)    
Common Class B [Member]            
Other income (expense):            
Weighted average shares outstanding, basic         2,717,466
Weighted average shares outstanding, diluted         2,717,466
Basic net (loss) income per share         $ 0.23
Diluted net (loss) income per share         $ 0.23